Skye Bioscience, Inc. (SKYE)
NASDAQ: SKYE · IEX Real-Time Price · USD
17.36
+1.11 (6.83%)
At close: Apr 17, 2024, 4:00 PM
17.38
+0.02 (0.12%)
After-hours: Apr 17, 2024, 7:38 PM EDT
Company Description
Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases.
The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension.
It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy.
It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021.
The company is headquartered in San Diego, California.
Skye Bioscience, Inc.
| Country | United States |
| Founded | 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 11 |
| CEO | Punit S. Dhillon B.A., BA |
Contact Details
Address: 11250 El Camino Real, Suite 100 San Diego, California 92130 United States | |
| Phone | (858) 410-0266 |
| Website | skyebioscience.com |
Stock Details
| Ticker Symbol | SKYE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001516551 |
| CUSIP Number | 83086J101 |
| ISIN Number | US83086J2006 |
| Employer ID | 45-0692882 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Punit S. Dhillon B.A. | Executive Chairman, President, Chief Executive Officer and Secretary |
| Kaitlyn Melanie Arsenault CPA | Chief Financial Officer |
| Dr. Christopher G. Twitty Ph.D. | Chief Scientific Officer |
| Tuan Tu Diep M.Sc. | Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 10, 2024 | EFFECT | Notice of Effectiveness |
| Apr 10, 2024 | 424B3 | Prospectus |
| Apr 10, 2024 | CERT | Certification by an exchange approving securities for listing |
| Apr 10, 2024 | 8-A12B | Registration of securities |
| Apr 4, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Apr 3, 2024 | 8-K | Current Report |
| Mar 27, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Mar 27, 2024 | D | Notice of Exempt Offering of Securities |
| Mar 22, 2024 | 10-K | Annual Report |
| Mar 13, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |